Tech Company Financing Transactions
CalciMedica Funding Round
CalciMedica, based in La Jolla, secured $21 million from Global Health Sciences Fund, Quark Venture and Sanderling Ventures.
Transaction Overview
Company Name
Announced On
3/12/2021
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series D
Investors
Global Health Sciences Fund (Lead Investor)
Quark Venture (Lead Investor) (Karimah Es Sabar)
Valence Life Sciences (Eric Roberts)
Proceeds Purpose
Proceeds from the financing will support the clinical development of CalciMedica's portfolio of CRAC channel inhibitors including Auxora which is being evaluated in an ongoing blinded placebo-controlled clinical trial in severe and critical COVID-19 pneumonia, with over 200 patients randomized to date, and in a Phase 2b trial in acute pancreatitis that will start enrolling patients in the coming weeks.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
505 Coast Blvd S. 202
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Leheny
Chief Financial Officer
Daniel Geffken
Chief Medical Officer
Sudarshan Hebbar
Chief Operating Officer
Michael Dunn
Chief Scientific Officer
Kenneth Stauderman
VP - General Counsel
John Dunn
Browse more venture capital transactions:
Prev: 3/12/2021: Hugging Face venture capital transaction
Next: 3/12/2021: ixlayer venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs